 Connection
Bethany Veo to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications Bethany Veo has written about Xenograft Model Antitumor Assays.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.121 |
|
|
|
-
Wang D, Ritz C, Luo Y, Suresh A, Pierce A, Veo B, Brunt B, Dahl N, Serkova N, Venkataraman S, Danis E, Kus K, Mazan M, Rzymski T, Vibhakar R. Transcriptional regulation of protein synthesis by mediator kinase represents a therapeutic vulnerability in MYC-driven medulloblastoma. Nat Commun. 2025 Dec 16; 16(1):11152.
Score: 0.046
-
Sobral LM, Walker FM, Madhavan K, Janko E, Donthula S, Danis E, Bompada P, Balakrishnan I, Wang D, Pierce A, Haag MM, Carstens BJ, Serkova NJ, Foreman NK, Venkataraman S, Veo B, Vibhakar R, Dahl NA. Targeting processive transcription for Myc-driven circuitry in medulloblastoma. Neuro Oncol. 2025 Oct 01; 27(10):2697-2710.
Score: 0.045
-
Marisetty AL, Lu L, Veo BL, Liu B, Coarfa C, Kamal MM, Kassem DH, Irshad K, Lu Y, Gumin J, Henry V, Paulucci-Holthauzen A, Rao G, Baladandayuthapani V, Lang FF, Fuller GN, Majumder S. REST-DRD2 mechanism impacts glioblastoma stem cell-mediated tumorigenesis. Neuro Oncol. 2019 06 10; 21(6):775-785.
Score: 0.029
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|